- Conditions
- Tuberculosis, Tuberculosis, Pulmonary
- Interventions
- TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 254
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Latent Tuberculosis, End Stage Renal Disease, Renal Transplant Candidate for Right Kidney, Renal Transplant Candidate for Left Kidney
- Interventions
- 1 month Rifapentine, Isoniazid and Vitamin B6
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Mycobacterium Avium-Intracellulare Infection, HIV Infections
- Interventions
- Azithromycin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- San Diego, California • Fort Bragg, North Carolina • Lackland Air Force Base, Texas
- Conditions
- Latent Tuberculosis Infection, Tuberculosis
- Interventions
- Not listed
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- Not listed
- Enrollment
- 21,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Richmond, California • Denver, Colorado + 7 more
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2000
- U.S. locations
- 15
- States / cities
- San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
- Conditions
- Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis, Tuberculosis, Extensively Drug-Resistant Tuberculosis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Tuberculosis, AIDS-related Complex
- Interventions
- Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo
- Drug · Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases
- Interventions
- RHB-204, Placebo
- Drug
- Lead sponsor
- RedHill Biopharma Limited
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 25
- States / cities
- Glendale, California • Palm Springs, California • Farmington, Connecticut + 21 more
- Conditions
- Mycobacterium Tuberculosis
- Interventions
- Moxifloxacin, Rifapentine
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Tuberculosis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Tuberculosis
- Interventions
- Not listed
- Lead sponsor
- Cepheid
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- Azacitidine Injection
- Drug
- Lead sponsor
- Andrew Dinardo
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection
- Interventions
- Hypertonic saline, Azithromycin, Ethambutol, Rifampin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • Portland, Oregon
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Ethambutol hydrochloride, Clarithromycin, Azithromycin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 24
- States / cities
- Berkeley, California • Mill Valley, California • Oakland, California + 17 more
- Conditions
- Tuberculosis
- Interventions
- BCG strain Connaught, BCG strain Danish, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Ciprofloxacin hydrochloride, Ethambutol hydrochloride, Amikacin sulfate, Azithromycin, Rifampin, Clofazimine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1994
- U.S. locations
- 16
- States / cities
- Torrance, California • Indianapolis, Indiana • St Louis, Missouri + 10 more
- Conditions
- Tuberculosis, Iron Deficiency Anemia
- Interventions
- CHICA Diagnosis Module, CHICA Placebo
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 2,239 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Latent Tuberculosis
- Interventions
- Rifapentine 600 mg orally, Isoniazid 900 mg orally, Pyridoxine 50 mg orally
- Drug
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Tuberculosis
- Interventions
- TMC207, rifapentine, rifampicin
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Mycobacterium Infections, Non-tuberculous
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Rifabutin
- Drug
- Lead sponsor
- Pharmacia
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 33
- States / cities
- Irvine, California • Sylmar, California • Denver, Colorado + 22 more
- Conditions
- Latent Tuberculosis
- Interventions
- LTBI video intervention
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Clarithromycin, Rifabutin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1996
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 24 more
- Conditions
- HIV, Tuberculosis
- Interventions
- Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more